Alan Nurden: Novel Platelet Inhibitors Expanding the Scope of Antithrombotic Therapy
Alan Nurden, Emeritus Research Director at CNRS, Co-Founder of the French National Reference Centre for Inherited Platelet Disorders (CRPP), shared a post on LinkedIn about a recent article by Thomas Kartika et al., published in Research and Practice in Thrombosis and Haemostasis, adding:
”This manuscript from Barry S Coller and his coworkers widens the perspective for ‘safe’ inhibitors of platelets in arterial thrombosis.
Known for their pioneering and highly successful studies on inhibitors of the alphaIIbbeta3 integrin starting with abciximab, they have now examined in detail the mechanisms whereby a series of Bruton tyrosine kinase inhibitors prevent platelet aggregation mediated through glycoprotein VI (GPVI), PEAR1 and Fcgamma-receptors.
Their work targeting specific signaling pathways opens the perspective for a novel approach to the treatment of virus or drug-induced thrombosis induced by immune complexes and perhaps, in the very rare cases of thrombotic-related complications seen in patients with inherited platelet disorders including Glanzmann thrombasthenia.
Highly recommended.”
Title: Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy
Authors: Thomas Kartika, Lorena Buitrago, Jihong Li, Charlotte Cunningham-Rundles, Barry S. Coller
Find more posts featuring Alan Nurden on Hemostasis Today.
-
Aug 24, 2026, 14:18The Way to a Safer Workplace for People With Bleeding Disorders – EHC
-
Aug 24, 2026, 14:09Stuart Andrew: NHS Blood and Transplant Strengthening the Blood Supply
-
Aug 24, 2026, 14:05Edward Lee Carter: Anticoagulation Stewardship is Moving From Recommendation to Measurement
-
Aug 24, 2026, 13:58Meera Chitlur: Transforming Care for Heavy Menstrual Bleeding at Children’s Hospital of Michigan
-
Aug 24, 2026, 13:49Heghine Khachatryan: Prepartum Acquired Hemophilia A and the Challenge of Maternal and Neonatal Bleeding
-
Aug 24, 2026, 13:44Neeraj Songara: Therapeutic Plasma Exchange in Severe Guillain–Barré Syndrome
-
Aug 24, 2026, 13:42Pall T. Onundarson: The Role of Measuring Treatment Effect in Optimizing DOAC and Warfarin Therapy
-
Aug 24, 2026, 13:39Emma Groarke: Somatic Mutations and Chromosomal Abnormalities in Bone Marrow Failure
-
Aug 24, 2026, 13:35Eileen Novins: The Marfan Foundation Supports The Work of The WHF